{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:31:49Z","timestamp":1760189509148},"reference-count":50,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 68-year-old male with history of hypertension and arthritis presented with bruising and increasing fatigue over several months. He was found to be thrombocytopenic (platelets 30), WCB 2.0 K\/mm3, Hg 11.6 g\/dL, ANC 870, and 1% circulating blasts. Bone marrow biopsy revealed 40%-50% cellular with multilineage dysplasia and 10% blasts. Cytogenetic genetic studies showed trisomy 2, and translocation (3;21). FISH studies for 5q, 7p, 8, 17p, and 20q abnormalities were negative. Molecular diagnostics were sent to a commercial laboratory to aid in prognostication. These studies showed mutations in TET2 (exons 1- 9 tested) and PHF6 (exons 1-9 tested). No abnormalities in other epigenetic regulators (DNMT3A, ASXL1), RNA splicing (SF3B1, SRSF2, URAF1, ZRSR2), transcription factors (RUNX1 or ETV6), or signaling (CBL, NRAS, KIT, JAK2, MPL) were detected. He was referred for consultation regarding initial treatment. In this elderly patient with preserved organ function and good performance status who is being considered for reduced intensity conditioned allogeneic hematopoietic cell transplant, what should the initial treatment be and can we use the molecular diagnostic results to guide therapy?<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.317","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"317-328","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Do somatic mutations in de novo MDS predict for response to treatment?"],"prefix":"10.1182","volume":"2015","author":[{"given":"Mark A.","family":"Schroeder","sequence":"first","affiliation":[{"name":"Washington University Medical School, St Louis, MO; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"12","key":"2019111704305717900_B1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111704305717900_B2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111704305717900_B3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2010.08082.x","article-title":"Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C","volume":"149","author":"Fenaux","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111704305717900_B4","first-page":"1997","article-title":"Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111704305717900_B5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2008.10.012","article-title":"Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden","volume":"15","author":"Warlick","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111704305717900_B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2008.12.003","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review","volume":"15","author":"Oliansky","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111704305717900_B7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbmt.2004.10.001","article-title":"Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome","volume":"11","author":"Scott","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111704305717900_B8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.leu.2403640","article-title":"Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome","volume":"19","author":"Nakai","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"2019111704305717900_B9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2019111704305717900_B10","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111704305717900_B11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111704305717900_B12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.13008","article-title":"Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS","volume":"167","author":"Zeidan","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111704305717900_B13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08893.x","article-title":"Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme","volume":"155","author":"van der Helm","year":"2011","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111704305717900_B14","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2014-04-522136","article-title":"Recent developments in myelodysplastic syndromes","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2019111704305717900_B15","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111704305717900_B16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111704305717900_B17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2019111704305717900_B18","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2019111704305717900_B19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2012","journal-title":"Nat Genet"},{"issue":"22","key":"2019111704305717900_B20","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111704305717900_B21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"7367","key":"2019111704305717900_B22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"10","key":"2019111704305717900_B23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/leu.2013.160","article-title":"NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes","volume":"27","author":"Murphy","year":"2013","journal-title":"Leukemia"},{"key":"2019111704305717900_B24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/asheducation-2013.1.504","article-title":"Prognostic models in myelodysplastic syndromes","volume":"2013","author":"Bejar","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2019111704305717900_B25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.leukres.2014.10.006","article-title":"The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes","volume":"39","author":"Zhang","year":"2015","journal-title":"Leuk Res"},{"issue":"17","key":"2019111704305717900_B26","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111704305717900_B27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2019111704305717900_B28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111704305717900_B29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/leu.2011.321","article-title":"SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications","volume":"26","author":"Damm","year":"2012","journal-title":"Leukemia"},{"issue":"15","key":"2019111704305717900_B30","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1182\/blood-2012-02-412296","article-title":"The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"issue":"14","key":"2019111704305717900_B31","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","article-title":"Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis","volume":"119","author":"Makishima","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2019111704305717900_B32","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"issue":"14","key":"2019111704305717900_B33","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","article-title":"Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes","volume":"119","author":"Damm","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2019111704305717900_B34","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"2019111704305717900_B35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/leu.2011.298","article-title":"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients","volume":"26","author":"Patnaik","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2019111704305717900_B36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00277-011-1352-7","article-title":"IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"91","author":"Lin","year":"2012","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111704305717900_B37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ajh.23596","article-title":"IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution","volume":"89","author":"Lin","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111704305717900_B38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res"},{"issue":"5","key":"2019111704305717900_B39","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111704305717900_B40","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","article-title":"Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes","volume":"29","author":"Thol","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111704305717900_B41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ajh.23410","article-title":"Prognostic impact of RAS mutations in patients with myelodysplastic syndrome","volume":"88","author":"Al-Kali","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111704305717900_B42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1309\/AJCPZRRL2DGC2ODA","article-title":"Myelodysplastic syndrome\/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a therapy-related disease associated with poor outcome","volume":"138","author":"Li","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2019111704305717900_B43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hon.976","article-title":"Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors","volume":"29","author":"Pollyea","year":"2011","journal-title":"Hematol Oncol"},{"issue":"12","key":"2019111704305717900_B44","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2011.170","article-title":"Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine","volume":"25","author":"Voso","year":"2011","journal-title":"Leukemia"},{"issue":"15","key":"2019111704305717900_B45","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2009-04-215814","article-title":"TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)","volume":"114","author":"Kosmider","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2019111704305717900_B46","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"2019111704305717900_B47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1756-8722-5-4","article-title":"Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide","volume":"5","author":"Sugimoto","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2019111704305717900_B48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3324\/haematol.2013.091249","article-title":"Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1\/2 mutations","volume":"99","author":"Lin","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2019111704305717900_B49","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3324\/haematol.2011.045559","article-title":"Rare occurrence of DNMT3A mutations in myelodysplastic syndromes","volume":"96","author":"Thol","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"2019111704305717900_B50","doi-asserted-by":"crossref","first-page":"E109","DOI":"10.1002\/ajh.23734","article-title":"SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution","volume":"89","author":"Lin","year":"2014","journal-title":"Am J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/317\/1251413\/bep00115000317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/317\/1251413\/bep00115000317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:31:23Z","timestamp":1573983083000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/317\/20766\/Do-somatic-mutations-in-de-novo-MDS-predict-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.317","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}